Lilly takes two shots at the Nectin goal
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
FDA knocks back Regeneron’s CD20 T-cell engager
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
Immutep approaches Lag3 crunch time
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Deals mask CytomX’s fundamental problem
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
